STTK Key Statistics, Chart & Performance
The current stock price of STTK is 4.75 USD. In the past month the price increased by 47.06%. In the past year, price increased by 299.16%.
STTK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About STTK
Company Profile
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 44 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Company Info
SHATTUCK LABS INC
500 W. 5Th Street, Suite 100
Austin TEXAS 78703 US
CEO: Taylor Schreiber
Employees: 44
Phone: 15129004690
SHATTUCK LABS INC / STTK FAQ
What does STTK do?
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 44 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Can you provide the latest stock price for SHATTUCK LABS INC?
The current stock price of STTK is 4.75 USD. The price increased by 2.37% in the last trading session.
What is the dividend status of SHATTUCK LABS INC?
STTK does not pay a dividend.
What is the ChartMill rating of SHATTUCK LABS INC stock?
STTK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for SHATTUCK LABS INC?
The Revenue of SHATTUCK LABS INC (STTK) is expected to decline by -81.56% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for SHATTUCK LABS INC?
SHATTUCK LABS INC (STTK) will report earnings on 2026-03-25, after the market close.
STTK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to STTK. When comparing the yearly performance of all stocks, STTK is one of the better performing stocks in the market, outperforming 99.23% of all stocks.
STTK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to STTK. No worries on liquidiy or solvency for STTK as it has an excellent financial health rating, but there are worries on the profitability.
STTK Financial Highlights
Over the last trailing twelve months STTK reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 33.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.03% | ||
| ROE | -59.22% | ||
| Debt/Equity | 0 |
STTK Forecast & Estimates
12 analysts have analysed STTK and the average price target is 4.08 USD. This implies a price decrease of -14.11% is expected in the next year compared to the current price of 4.75.
For the next year, analysts expect an EPS growth of 46.95% and a revenue growth -81.56% for STTK